Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
复制标题
DOI：
10.1586/14760584.2016.1115727
复制
发表时间：
2016
影响因子：
6.2
通讯作者：
Whitehead SS
中科院分区：
文献类型：
--
作者：
Whitehead SS
登革热是由四种不同血清型的登革热病毒(DENV)引起的，由于对DENV的部分免疫可能会在随后感染DENV时导致更严重的疾病，因此开发针对登革热的多价疫苗并非易事。研发最深入的疫苗是赛诺菲巴斯德生产的四价减毒活疫苗Cyd™。尽管多剂量疫苗显示了对严重登革热的保护作用，但其总体效果受到DENV血清型、接种时的血清状态、地区和年龄的限制。国家过敏和传染病研究所已经开发出LATV登革热疫苗TV003/TV005。单剂TV003或TV005可诱导74%~92%(TV003)和90%(TV005)黄病毒血清阴性成人对4种DENV血清型的血清转换，并在6~12个月后对第二剂疫苗产生接近灭菌的免疫。比较了TV003/TV005与CyD™在结构、感染性和免疫应答等方面的重要差异。
Dengue is caused by four serotype-distinct dengue viruses (DENVs), and developing a multivalent vaccine against dengue has not been straightforward since partial immunity to DENV may predispose to more severe disease upon subsequent DENV infection. The vaccine that is furthest along in development is CYD™, a live attenuated tetravalent vaccine (LATV) produced by Sanofi Pasteur. Although the multi-dose vaccine demonstrated protection against severe dengue, its overall efficacy was limited by DENV serotype, serostatus at vaccination, region, and age. The National Institute of Allergy and Infectious Diseases has developed the LATV dengue vaccines TV003/TV005. A single dose of either TV003 or TV005 induced seroconversion to four DENV serotypes in 74%–92% (TV003) and 90% (TV005) of flavivirus seronegative adults and elicited near-sterilizing immunity to a second dose of vaccine administered 6–12 months later. The important differences in the structure, infectivity, and immune responses to TV003/TV005 are compared with CYD™.